Clinical trials: T2DM (Type 2 Diabetes Mellitus)
Type 2 Diabetes Mellitus (T2DM)
2025 Hypoglycemia Early-Warning and Physician-Nurse Collaborative Management Trial in Type 2 Diabetes
The goal of this clinical study is to learn whether a physician-nurse collaborative intervention guided by an Intelligent Hypoglycemia Risk Early-Warning System can reduce hypoglycemia and improve glycemic control in hospitalized…
- Trial name
- NCT07314749
- Testing
- Physician-Nurse Collaborative Intervention Guided by Intelligent Hypoglycemia Risk Early-Warning System, Usual Care
- Where
- China
- Volunteers
- 1,255 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Type 2 Diabetes Mellitus (T2DM)
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with…
- Trial name
- NCT06327815
- Testing
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets
- Where
- 35 sites in China
- Volunteers
- 633 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Obesity
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
- Trial name
- NCT07172867
- Testing
- HT-6184, Semaglutide 1 mg
- Where
- United Arab Emirates
- Sponsor
- Halia Therapeutics, Inc.
Type 2 Diabetes Mellitus
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes
The glucagon-like peptide 1 (GLP-1) agonist exenatide represents an effective therapy in patients with type 2 diabetes mellitus (T2DM), which also seems to have some important non-glycemic effects.
- Trial name
- NCT02380521
- Testing
- Exenatide once weekly (BYDUREON™)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Palermo
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Renal Hypoxia
- Trial name
- ROCKIES (NCT04027530)
- Testing
- Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes
A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)
The goal of this clinical trial is to learn about inour study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration.
- Trial name
- NCT06191328
- Testing
- Chiglitazar sodium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yufan Wang
Diabetes, Hypothyroidism
Thyroid Study Type 2 Diabetes Mellitus (T2DM)
Background of the study: Thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to promote weight loss, which could be beneficial for treating obesity, and type 2 diabetes.
- Trial name
- NCT01379170
- Testing
- Euthyrox (levothyroxine)
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood…
- Trial name
- NCT06836479
- Testing
- NOURISH Diet, Self-Selected Diet (Control)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Type 2 Diabetes Mellitus (T2DM), Stroke
WhatsApp-Based Education Program for Stroke Patients
Stroke is one of the leading causes of death and disability worldwide, with type 2 diabetes mellitus (T2DM) being a major risk factor that doubles the risk of ischemic stroke.
- Trial name
- WEPS-P (NCT07207694)
- Testing
- WhatsApp-based education group, Active Comparator: Routine Education
- Volunteers
- 84 people
- Sponsor
- Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Type 2 Diabetes
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
This trial is conducted in China. The aim of the trial is to compare the efficacy and safety of GZR101 and insulin degludec/insulin aspart in insulin naïve or insulin treated subjects with type 2 diabetes.
- Trial name
- NCT06199505
- Testing
- GZR101, insulin degledec/insulin aspart
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 2, Albuminuria
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and…
- Trial name
- CANVAS-R (NCT01989754)
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 341 sites in United States, Argentina and 23 more
- Volunteers
- 5,813 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of…
- Trial name
- Cilo-Asa (NCT07719894)
- Testing
- Cilostazol, Aspirin
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes Mellitus
Genetic Variants and Phenotypic Characteristics of Patients With T2DM
Background: Genetic risk-markers associated with T2DM are thoroughly studied. So far, only a few genetic variants, also termed single nucleotide polymorphisms (SNP's), have been replicated in several studies and each of them…
- Trial name
- GenVarT2DM (NCT00760292)
- Where
- Denmark
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Diabetes Mellitus, Type 2, Erectile Dysfunction
Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients
Erectile dysfunction (ED) is a common form of organic sexual dysfunction in males with diabetes, with estimated incidence rates between 35 and 75%.
- Trial name
- ECSIITED (NCT01468519)
- Testing
- Insulin
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Jothydev's Diabetes and Research Centre
Type 2 Diabetes Mellitus (T2DM), Atrial Fibrillation (AF)
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
Objective To compare, in patients with Type 2 Diabetes Mellitus (T2DM) and Atrial Fibrillation (AF) undergoing radiofrequency ablation (RFA), whether strict weight management and glycemic control based on Glucagon-like Peptide-1…
- Trial name
- NCT06660134
- Testing
- Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Shanghai Chest Hospital
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
- Trial name
- NCT00337610
- Testing
- sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies
CMR in T2DM: The NSR Cohort
This study aims to investigate the myocardial phenotype of patients with type 2 diabetes. From 2016-2019 the investigators recruited a cohort of 296 subjects with type 2 diabetes.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies, Cardiovascular Magnetic Resonance Imaging, Coronary Microvascular Dysfunction
- Trial name
- NCT05915260
- Testing
- All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion
- Where
- Denmark
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Slagelse Hospital
Type 2 Diabetes, Glucose Tolerance Impaired
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose…
- Conditions
- Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
- Trial name
- NCT05093517
- Testing
- REMD-477
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obesity, Type 2 Diabetes Mellitus (T2DM)
Magnetic Duodeno-Ileal Chile Study
The objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06613724
- Testing
- Magnet System, DI Biofragmentable
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.